These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18625688)

  • 1. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.
    Lin JH; Duggan DE; Chen IW; Ellsworth RL
    Drug Metab Dispos; 1991; 19(5):926-32. PubMed ID: 1686238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
    Steinke W; Ahr HJ; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.
    Lin JH; Chen IW; deLuna FA
    Drug Metab Dispos; 1994; 22(3):400-5. PubMed ID: 8070316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
    He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses.
    Nieto JE; Maher O; Stanley SD; Knych HK; Snyder JR
    Am J Vet Res; 2013 Apr; 74(4):550-6. PubMed ID: 23531062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
    Cho YB; Kim KH; Kim DK
    Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
    Usui T; Watanabe T; Higuchi S
    Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of medetomidine.
    Salonen JS
    Acta Vet Scand Suppl; 1989; 85():49-54. PubMed ID: 2571277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.
    Lin JH; Chen IW; Duggan DE
    Drug Metab Dispos; 1992; 20(4):473-8. PubMed ID: 1356720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study.
    Juillard A; Falgayrac G; Cortet B; Vieillard MH; Azaroual N; Hornez JC; Penel G
    Bone; 2010 Nov; 47(5):895-904. PubMed ID: 20656084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of alendronate: an overview.
    Lin JH; Russell G; Gertz B
    Int J Clin Pract Suppl; 1999 Apr; 101():18-26. PubMed ID: 12669737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
    Lin JH; Chen IW; Deluna FA
    Drug Metab Dispos; 1993; 21(5):800-4. PubMed ID: 7902239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals.
    Wingen F; Schmähl D
    Arzneimittelforschung; 1987 Sep; 37(9):1037-42. PubMed ID: 3435598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
    Lin JH; Chen IW; deLuna FA; Hichens M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):670-5. PubMed ID: 8246140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
    Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
    J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
    Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.
    Li Q; Xie LH; Haeberle A; Zhang J; Weina P
    Am J Trop Med Hyg; 2006 Nov; 75(5):817-26. PubMed ID: 17123971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fate of erythritol after single oral administration to rats and dogs.
    Noda K; Nakayama K; Modderman J
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 2):S206-13. PubMed ID: 8933635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and excretion of dalbavancin in the rat.
    Cavaleri M; Riva S; Valagussa A; Guanci M; Colombo L; Dowell J; Stogniew M
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii31-5. PubMed ID: 15750035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.